The total CAPEX planned for the site is around Rs. 190 crore, off which Rs. 163 crore has been raised from the IPO that the company concluded in June 2022 and remaining Rs. 27 crore funded from internal accruals. The trial runs have been started today and the commercial production of the plant will start within next ten days.

The manufacturing site 3 will add capacities to the north of 3500 MT per annum for production of five new specialty chemicals / intermediates for the Pharma Sector, which will be launched here.